close 74% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

Home・Aandelen Lijst・Merck KGaA
Search

Merck KGaA

Gesloten

121.85 -3.02

Strong Buy

Prijsupdate 3 apr 2025, 15:29 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

121.5

Max

126.6

Belangrijke statistieken

By Trading Economics

Inkomsten

-142M

667M

Verkoop

152M

5.4B

K/W

Sectorgemiddelde

26.27

63.778

EPS

2.2

Dividendrendement

1.34

Winstmarge

12.311

EBITDA

85M

1.6B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+39.46% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.34%

2.39%

Volgende Winsten

15 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

33B

98B

Vorige openingsprijs

124.87

Vorige sluitingsprijs

121.85

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

N/A / 126.35 Steun & Weerstand

Merck KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2025, 06:27 UTC

Winsten

Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

DJ

Lezen

11 feb 2025, 07:03 UTC

Acquisities, Fusies, Overnames

Germany's Merck in Talks to Buy SpringWorks Therapeutics

DJ

Lezen

10 feb 2025, 16:38 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

DJ

Lezen

6 mrt 2025, 11:18 UTC

Marktinformatie
Winsten

Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk

DJ

Lezen

6 mrt 2025, 11:14 UTC

Marktinformatie

Merck KGaA's Outlook Signals Greater Transparency -- Market Talk

DJ

Lezen

6 mrt 2025, 08:20 UTC

Marktinformatie
Winsten

Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 Adj EPS EUR8.63

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 EBIT EUR3.645B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 After-Tax Profit EUR2.79B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 EBITDA EUR5.78B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 Sales EUR21.16B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA Keeps Dividend at EUR2.20

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Analysts Saw Merck KGaA 2024 Sales at EUR21.14B

DJ

Lezen

6 mrt 2025, 06:00 UTC

Winsten

Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B

DJ

Lezen

11 feb 2025, 16:45 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk

DJ

Lezen

11 feb 2025, 10:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

DJ

Lezen

11 feb 2025, 10:52 UTC

Marktinformatie
Acquisities, Fusies, Overnames

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

DJ

Lezen

6 jan 2025, 13:08 UTC

Acquisities, Fusies, Overnames

Merck KGaA: Transaction closed on Dec. 23, 2024

DJ

Lezen

6 jan 2025, 13:07 UTC

Acquisities, Fusies, Overnames

Merck KGaA: Didn't Disclose Financial Details

DJ

Lezen

6 jan 2025, 13:06 UTC

Acquisities, Fusies, Overnames

Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio

DJ

Lezen

6 jan 2025, 13:04 UTC

Acquisities, Fusies, Overnames

Merck KaA Acquires HUB Organoids Holding B.V. to Expand Its Next-Generation Biology Portfolio

DJ

Lezen

17 dec 2024, 13:05 UTC

Acquisities, Fusies, Overnames

Merck: Deal Expected to Close By End Dec. 2024

DJ

Lezen

17 dec 2024, 13:04 UTC

Acquisities, Fusies, Overnames

Merck: Terms of Deal Undisclosed

DJ

Lezen

17 dec 2024, 13:04 UTC

Acquisities, Fusies, Overnames

Merck Signs Pact to Buy HUB Organoids

DJ

Lezen

17 dec 2024, 13:03 UTC

Acquisities, Fusies, Overnames

Merck: Acquisition Advances Next Gen Biology Portfolio

DJ

Lezen

17 dec 2024, 13:03 UTC

Acquisities, Fusies, Overnames

Merck to Buy HUB Organoids Holding

DJ

Lezen

14 nov 2024, 11:15 UTC

Marktinformatie

Merck KGaA's Sales Target Dragged by Muted China Outlook -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Merck KGaA Prognose

Koersdoel

By TipRanks

39.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 175.86 EUR  39.46%

Hoogste 190 EUR

Laagste 160 EUR

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

7

Buy

2

Hold

0

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Merck KGaA - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 126.35Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

All events are bearish.

Gemiddeld Termijn

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Lange Termijn

Strong Bearish Evidence

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merck KGaA

There is no Profile data available for MRK.BE.

Andere aandelen uit de sector

SAN

Sanofi SA

99.62

↓-0.56%

EI

EssilorLuxottica SA

248.8

↓-7.03%

SHL.DE

Siemens Healthineers AG

46.38

↓-7.09%

ARGX

Argenx SE

535.8

↑ +0.3%

FRE

Fresenius SE & Co KGaA

39.76

↑ +0.86%